Why the Jackson Hole Symposium is a Big Deal
This Friday, Federal Reserve Chair Jerome Powell will make a speech at the annual Jackson Hole Symposium. The focus is "Labor Markets in Transition: Demographics, Productivity, and Macroeconomic Policy.”The all-day event is a bigger deal than in previous years. President Trump demanded that the Fed Chair be replaced. He wanted a 300-basis-point cut, even though 25 bps – 50 bps would suffice. Still, any excessive rate cut overstimulates the economy. That would cause inflation. A weaker job market would lead to stagflation.Investors are positioning for a rate cut. The longer-term treasury bill ETFs like the 7-10 Year (IEF) and 20+ Year (TLT) pulled back in the last week. Bank stocks like Wells Fargo (WFC), JPMorgan Chase (JPM), and Citigroup (C) are in a holding pattern. They could re-test recent highs if Powell hints that rates would fall sometime in 2025.Powell might discuss a new Fed policy framework. That would influence central bank rate decisions in other countries. This week, central banks in Iceland and Sweden will announce their rate decisions.Inflation is decidedly above the Fed’s 2% goal. The CME FedWatch tool, however, is predicting a 25-bps cut with an over 90% probability. July’s consumer price index (CPI) and producer price index (PPI) did not support a rate cut. Inflation rates are still too high. Fortunately, tariffs did not lead to an increase in inflation rates.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


